Mice with a mutation in the thyroid hormone receptor β gene spontaneously develop thyroid carcinoma: A mouse model of thyroid carcinogenesis

Thyroid

Volumn 12, Issue 11, 2002, Pages 963-969

  Suzuki, Hideyo ^a   Willingham, Mark C ^b   Cheng, Sheue yann ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS RECEPTOR; GENE PRODUCT; THYROID HORMONE RECEPTOR; THYROID HORMONE RECEPTOR BETA; THYROTROPIN; UNCLASSIFIED DRUG;

ANAPLASTIC CARCINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INVASION; CARCINOGENESIS; CONTROLLED STUDY; DISEASE ASSOCIATION; EPITHELIUM; GENE CONTROL; GENE LOCUS; GENE MUTATION; HEART METASTASIS; HISTOPATHOLOGY; HYPERPLASIA; HYPOPHYSIS THYROID SYSTEM; LUNG METASTASIS; METASTASIS; MOLECULAR GENETICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; THYROID CARCINOMA; THYROID FOLLICLE;

EID: 6444245375     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/105072502320908295     Document Type: Article

References (26)

1. Gillenwater AM, Weber RS 1997 Thyroid carcinoma. Cancer Treat Res 90:149-169.
2. Baloch ZW, LiVolsi VA 2002 Follicular-patterned lesions of the thyroid: The bane of the pathologist. Am J Clin Pathol 117:143-150.
3. Rosai J, Carcangiu ML, DeLellis RA 1992 Tumors of the Thyroid Gland. Armed Forces Institute of Pathology, Third Series, Fascicle 5, pp 49-63.
4. Jhiang SM 2000 The RET proto-oncogene in human cancers. Oncogene 19:5590-5597.
5. Powell DJ Jr, Russell J, Nibu K, Li G, Rhee E, Liao M, Goldstein M, Keane WM, Santoro M, Fusco A, Rothstein JL 1998 The RET/PTC3 oncogene: Metastatic solid-type papillary carcinomas in murine thyroids. Cancer Res 58:5523-5528.
6. Santoro M, Chiappetta G, Cerrato A, Salvatore D, Zhang L, Manzo G, Picone A, Portella G, Santelli G, Vecchio G, Fusco A 1996 Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTC1 oncogene in transgenic mice. Oncogene 12:1821-1826.
7. Jhiang SM, Sagartz JE, Tong Q, Parker-Thomburg J, Capen CC, Cho JY, Xing S, Ledent C 1996 Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas. Endocrinology 137:375-378.
8. Cheng S-y 2000 Multiple mechanisms for regulation of the transcriptional activity of thyroid hormone receptors. Rvw Endocrine Metabolic Disorders 1:9-18.
9. Damm K 1993 ErbA: Tumor suppressor turned oncogene? FASEB J 7:904-909.
10. Wolffe AP, Collingwood TN, Li Q, Yee J, Urnov F, Shi YB 2000 Thyroid hormone receptor, v-ErbA, and chromatin. Vitam Horm 58:449-492.
11. Barlow C, Meister B, Lardelli M, Lendahl U, Vennstrom B 1994 Thyroid abnormalities and hepatocellular carcinoma in mice transgenic for v-erbA. EMBO J 13:4241-4250.
12. Lin KH, Shieh HY, Chen SL, Hsu HC 1999 Expression of mutant thyroid hormone nuclear receptors in human hepatocellular carcinoma cells. Mol Carcinog 26:53-61.
13. Kamiya Y, Puzianowska-Kuznicka M, McPhie P, Nauman J, Cheng S-y, Nauman A 2002 Expression of mutant thyroid hormone nuclear receptors associated with human renal clear cell carcinoma. Carcinogenesis 23:25-33.
14. Puzianowska-Kuznicka M, Krystyniak A, Madej A, Cheng SY, Nauman J 2002 Functionally impaired TR mutants are present in thyroid papillary cancer. J Clin Endocrinol Metab 87:1120-1128.
15. Ando S, Sarlis NJ, Oldfield EH, Yen PM 2001 Somatic mutation of TRβ can cause a defect in negative regulation of TSH in a TSH-secreting pituitary tumor. Clin Endocrinol Metab 86:5572-5576.
16. Ando S, Sarlis NJ, Krishnan J, Feng X, Refetoff S, Zhang MQ, Oldfield EH, Yen PM 2001 Aberrant alternative splicing of thyroid hormone receptor in a TSH-secreting pituitary tumor is a mechanism for hormone resistance. Mol Endocrinol 15:1529-1538.
17. Kaneshige M, Kaneshige K, Zhu XG, Dace A, Garrett L, Carter TA, Kazlauskaite R, Pankratz DG, Wynshaw-Boris A, Weintraub B, Billingham MC, Barlow C, Cheng SY 2000 Mice with a targeted mutation in the thyroid hormone β receptor gene exhibit impaired growth and resistance to thyroid hormone. Proc Natl Acad Sci USA 97:13209-13214.
18. Weiss RE, Refetoff, S 2000 Rvw Endocr Metab Disord 1:97-108.
19. Parrilla R, Mixson AJ, McPherson JA, McClaskey JH, Weintraub BD 1991 Characterization of seven novel mutations of the c-erbA β gene in unrelated kindreds with generalized thyroid hormone resistance. Evidence for two "hot spot" regions of the ligand binding domain. J Clin Invest 88:2123-2130.
20. Ono S, Schwartz ID, Mueller OT, Root AW, Usala SJ, Bercu BB 1991 Homozygosity for a dominant negative thyroid hormone receptor gene responsible for generalized resistance to thyroid hormone. J Clin Endocrinol Metab 73:990-994.
21. Meier CA, Dickstein BM, Ashizawa K, McClaskey JH, Muchmore P, Ransom SC, Merke JB, Hao EU, Usala SJ, Bercu BB, Cheng SY, Weintraub BD 1992 Variable transcriptional activity and ligand binding of mutant β1 3,3′,5-triiodo-L-thyronine receptors from four families with generalized resistance to thyroid hormone. Mol Endocrinol 6:248-258.
22. Lee, E. T 1992 Statistical Methods for Survival Data Analysis. John Wiley & Sons, New York.
23. La Perle KM, Jhiang SM, Capen CC 2000 Loss of p53 promotes anaplasia and local invasion in ret/PTC1-induced thyroid carcinomas. Am J Pathol 157:671-677.
24. Powell DJ Jr, Russell JP, Li G, Kuo BA, Fidanza V, Huebner K, Rothstein JL 2001 Altered gene expression in immunogenic poorly differentiated thyroid carcinomas from RET/PTC3p53-/-mice. Oncogene 20:3235-3246.
25. Schaller RT Jr, Stevenson JK 1966 Development of carcinoma of the thyroid in iodine-deficient mice. Cancer 19:1063-1080.
26. Sagartz JE, Jhiang SM, Tong Q, Capen CC 1997 Thyroid-stimulating hormone promotes growth of thyroid carcinomas in transgenic mice with targeted expression of the ret/PTC1 oncogene. Lab Invest 76:307-318.